THE Johnson & Johnson, or Janssen, Covid-19 vaccine is a single-dose vaccine to prevent Covid-19.
This Snapshot feature addresses potential side effects and the controversies surrounding the recent blood clotting incidents.
The Johnson & Johnson Covid-19 vaccine, also called Ad26.COV2.S, was developed by Janssen Pharmaceuticals of Johnson & Johnson.
It is a single-dose vaccine, which differentiates it from two-dose COVID-19 vaccines, such as the ones from Pfizer and Moderna.
In early 2021, the Food and Drug Administration (FDA)Trusted Source and, after a recommendation from the European Medicines Agency (EMA), the European Commission issued emergency and conditional authorization for the Johnson & Johnson vaccine for individuals aged 18 years and older. The vaccine has been approved for emergency use in 40 countries.
Stay informed with live updates on the current Covid-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.
However, the FDA recommended a pause in the vaccine’s use, as a precautionary measure following a small number of rare blood clot incidents.
At the same time, Johnson & Johnson delayed the distribution of the vaccine in Europe while the EMA conducted its own review.
On April 20, the company announced it would resume distribution of its vaccine in the European Union but with a safety warning, after the EMA concluded that the vaccine’s benefits continue to outweigh its risks.
After halting vaccination in the United States a few weeks ago, the FDA and the CDC recently recommendedTrusted Source that vaccinations resume.
They noted, however, that women under the age of 50 should be aware of the risk of rare blood clots.
Moreover, both agencies want women to know that alternative Covid-19 vaccines are available, for which there are currently no reports of rare blood clots.
The World Health Organization (WHO) Trusted Source has stated that, while it continues to monitor the safety responses from regulatory agencies, the vaccine is safe and effective against the severe risks of Covid-19.
The vaccine is categorized as a viral vector vaccine.